Ohio overdose deaths plummeted in 2024
Ohio drug overdose deaths fell by more than 35% from 2023 to 2024, according to preliminary CDC data — one of the most significant decreases in the country.
The big picture: Fatal overdoses last year dropped to their lowest annual level since 2019.
They initially rose during the COVID pandemic, but have been falling since 2023.
Zoom in: Total overdose deaths in Cuyahoga County totaled 435 in 2024, according to county medical examiner Thomas Gilson.
It's the first time the figure has dropped below 500 in a decade.
The intrigue: Gilson has attributed the decline to the diminishing availability of fentanyl in the community, but has warned that new drugs might take its place.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
20 minutes ago
- New York Times
Palantir's Collection of Disease Data at C.D.C. Stirs Privacy Concerns
The Centers for Disease Control and Prevention's plans to consolidate data on diseases like measles and polio are raising concerns about patient privacy, delays in spotting long-term trends and ways the Trump administration may use the information. The agency told state officials earlier this week that it would shift disease information to a new system managed by Palantir, the data analysis and technology firm co-founded by Peter Thiel. The change is not entirely unexpected. The Covid pandemic revealed that the C.D.C.'s data systems were antiquated, hobbling the country's response in the crucial early months. A plan to modernize and consolidate the agency's data systems began during the Biden administration. But news that the Trump administration has expanded Palantir's work across the federal government in recent months, allowing it to compile detailed information about Americans, has introduced a new layer of anxiety and mistrust among state and local officials about sharing data with the C.D.C. Palantir's systems, including those at the C.D.C., rely on a platform called Foundry that could merge information from different agencies. The Department of Health and Human Services, the Food and Drug Administration and the National Institutes of Health all use Foundry. Some officials worry that a sprawling data collection system could expose or endanger people with sensitive health needs, like gender care, reproductive health care or disabilities. Some labor and other advocacy groups have tried to block the Trump administration from sharing data across agencies. Want all of The Times? Subscribe.
Yahoo
29 minutes ago
- Yahoo
Mayor Walsh to proclaim Tourette Syndrome Awareness Day
SYRACUSE. N.Y. (WSYR-TV)– Syracuse Mayor Walsh Ben has declared June 7 Tourrette Syndrome Awareness Day in Syracuse, NY. Tourette Syndrome is a neurological condition that involves involuntary, repetitive movements and vocalizations known as tics. Mayor Walsh, Councilmember Nave, families impacted by Tourette Syndrome and other Tic Disorders, and members of the Syracuse community will gather on the steps of City Hall on June 6, at noon to announce the proclamation. Recognizing the disorder will help raise awareness, educate, and promote inclusion for individuals living with Tourette Syndrome and other Tic Disorders. It will also increase supportive environments where people, regardless of their neurological disorder, can grow. According to the Centers for Disease Control and Prevention (CDC), approximately one in 50 school-aged children in the US are affected by Tourette Syndrome or a Tic Disorder, including many families in Syracuse. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Indianapolis Star
an hour ago
- Indianapolis Star
Moderna Announces Update on Investigational Pandemic Influenza Program
Phase 1/2 H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMBRIDGE, MA / ACCESS Newswire Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT05972174) evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine, mRNA-1018, in approximately 300 healthy adults aged 18 years and older. The interim results focus on a vaccine candidate targeting the H5 avian influenza virus subtype. The Company had previously expected to advance the program to late-stage development with the U.S. Department of Health and Human Services (HHS); however, today Moderna received notice that HHS will terminate the award for the late-stage development and right to purchase pre-pandemic influenza vaccines. 'While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats.' The Phase 1/2 study evaluated a two-dose regimen of Moderna's investigational avian influenza vaccine. mRNA-1018 demonstrated a rapid, potent and durable immune response. At baseline, pre-existing immunity was minimal, with only 2.1% of participants showing hemagglutination inhibition (HAI) antibody titers ≥1:40, an HAI titer considered to correlate with protection. At Day 43, three weeks after the second vaccination, 97.8% of participants achieved titers ≥1:40 with a 44.5-fold increase of titers from baseline. The investigational vaccine was generally well-tolerated, with no dose-limiting tolerability concerns observed. Most solicited adverse reactions were Grade 1 or 2 and did not increase significantly with number of doses or between first and second doses. Further data is expected to be submitted for presentation at an upcoming scientific meeting. Moderna will explore alternatives for late-stage development and manufacturing of the H5 program consistent with the Company's strategic commitment to pandemic preparedness. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the clinical development of mRNA-1018, the safety and immunogenicity data from the Phase 1/2 study; the cancellation of the development contract for Moderna's pandemic flu program by the U.S. Department of Health and Human Services; and the exploration of alternative paths for development of the vaccine program. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire
